What have we learned about randomized, controlled trials in neonatal sepsis?

Area of Science:

• Neonatal Medicine
• Clinical Trials Methodology
• Evidence-Based Practice

Background:

• Randomized controlled trials (RCTs) are essential for evaluating neonatal sepsis therapies.
• Most existing neonatal RCTs are underpowered to detect meaningful improvements in disability-free survival.
• Incomplete evaluation of neonatal therapies hinders clinical progress.

Purpose of the Study:

• To identify strategies for conducting robust RCTs in neonatal sepsis.
• To recognize therapies that enhance disability-free survival in neonates.
• To address the limitations of small sample sizes in current neonatal research.

Main Methods:

• Rapid literature review to synthesize existing knowledge.
• Analysis of methodological challenges in neonatal RCTs.
• Exploration of strategies to increase sample sizes and reliability.

Main Results:

• RCTs require large sample sizes (thousands) to reliably detect moderate improvements in disability-free survival.
• Current neonatal trials are often too small, leading to inconclusive results.
• International collaboration, simplified data, cost-effective recruitment, and broader inclusion criteria are necessary.
• Prospective meta-analysis of individual patient data is a promising approach.

Conclusions:

• Prospective meta-analysis of individual patient data can facilitate large-scale, randomized evidence generation in neonatal sepsis.
• This strategy combines the strengths of megatrials with practical advantages of international collaboration.
• It enables more reliable evaluation of therapies to improve neonatal outcomes.